 | • レポートコード：MRC2102QY10053 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、140ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界のオピオイド誘発性便秘市場について種類別（臭化メチルナルトレキソン、ルビプロストン、ナロキセゴール、その他）、用途別（病院、薬局）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・オピオイド誘発性便秘市場の概要 ・世界の主要地域別オピオイド誘発性便秘市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界のオピオイド誘発性便秘市場規模2015-2026：種類別（臭化メチルナルトレキソン、ルビプロストン、ナロキセゴール、その他） ・世界のオピオイド誘発性便秘市場規模2015-2026：用途別（病院、薬局） ・オピオイド誘発性便秘の米国市場規模2015-2020 ・オピオイド誘発性便秘のヨーロッパ市場規模2015-2020 ・オピオイド誘発性便秘の中国市場規模2015-2020 ・オピオイド誘発性便秘の日本市場規模2015-2020 ・オピオイド誘発性便秘の東南アジア市場規模2015-2020 ・オピオイド誘発性便秘のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・オピオイド誘発性便秘の製造コスト分析 ・販売チャネル、流通業者、顧客 ・オピオイド誘発性便秘の市場動向・機会・課題 ・調査の結論 |
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.
Market Analysis and Insights: Global Opioid-Induced Constipation Market
The global Opioid-Induced Constipation market size is projected to reach US$ 3377 million by 2026, from US$ 2578.3 million in 2020, at a CAGR of 4.6% during 2021-2026.
Global Opioid-Induced Constipation Scope and Market Size
The global Opioid-Induced Constipation market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Opioid-Induced Constipation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Opioid-Induced Constipation market is segmented into
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Segment by Application, the Opioid-Induced Constipation market is segmented into
Hospital
Pharmacy
The Opioid-Induced Constipation market is analysed and market size information is provided by regions (countries). Segment by Application, the Opioid-Induced Constipation market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Opioid-Induced Constipation Market Share Analysis
Opioid-Induced Constipation market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Opioid-Induced Constipation business, the date to enter into the Opioid-Induced Constipation market, Opioid-Induced Constipation product introduction, recent developments, etc.
The major vendors covered:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
1 Opioid-Induced Constipation Market Overview
1.1 Opioid-Induced Constipation Product Scope
1.2 Opioid-Induced Constipation Segment by Type
1.2.1 Global Opioid-Induced Constipation Sales by Type (2020-2026)
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Opioid-Induced Constipation Segment by Application
1.3.1 Global Opioid-Induced Constipation Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Opioid-Induced Constipation Market Estimates and Forecasts (2015-2026)
1.4.1 Global Opioid-Induced Constipation Sales Growth Rate (2015-2026)
1.4.2 Global Opioid-Induced Constipation Revenue and Growth Rate (2015-2026)
1.4.3 Global Opioid-Induced Constipation Price Trends (2015-2026)
2 Opioid-Induced Constipation Estimate and Forecast by Region
2.1 Global Opioid-Induced Constipation Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Opioid-Induced Constipation Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Opioid-Induced Constipation Sales Market Share by Region (2015-2020)
2.2.2 Global Opioid-Induced Constipation Revenue Market Share by Region (2015-2020)
2.3 Global Opioid-Induced Constipation Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Opioid-Induced Constipation Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Opioid-Induced Constipation Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Opioid-Induced Constipation Estimates and Projections (2015-2026)
2.4.2 Europe Opioid-Induced Constipation Estimates and Projections (2015-2026)
2.4.3 China Opioid-Induced Constipation Estimates and Projections (2015-2026)
2.4.4 Japan Opioid-Induced Constipation Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Opioid-Induced Constipation Estimates and Projections (2015-2026)
2.4.6 India Opioid-Induced Constipation Estimates and Projections (2015-2026)
3 Global Opioid-Induced Constipation Competition Landscape by Players
3.1 Global Top Opioid-Induced Constipation Players by Sales (2015-2020)
3.2 Global Top Opioid-Induced Constipation Players by Revenue (2015-2020)
3.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Opioid-Induced Constipation as of 2019)
3.4 Global Opioid-Induced Constipation Average Price by Company (2015-2020)
3.5 Manufacturers Opioid-Induced Constipation Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Opioid-Induced Constipation Players (Opinion Leaders)
4 Global Opioid-Induced Constipation Market Size by Type
4.1 Global Opioid-Induced Constipation Historic Market Review by Type (2015-2020)
4.1.1 Global Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
4.1.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2015-2020)
4.1.3 Global Opioid-Induced Constipation Price by Type (2015-2020)
4.2 Global Opioid-Induced Constipation Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Opioid-Induced Constipation Sales Forecast by Type (2021-2026)
4.2.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2021-2026)
4.2.3 Global Opioid-Induced Constipation Price Forecast by Type (2021-2026)
5 Global Opioid-Induced Constipation Market Size by Application
5.1 Global Opioid-Induced Constipation Historic Market Review by Application (2015-2020)
5.1.1 Global Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
5.1.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2015-2020)
5.1.3 Global Opioid-Induced Constipation Price by Application (2015-2020)
5.2 Global Opioid-Induced Constipation Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Opioid-Induced Constipation Sales Forecast by Application (2021-2026)
5.2.2 Global Opioid-Induced Constipation Revenue Forecast by Application (2021-2026)
5.2.3 Global Opioid-Induced Constipation Price Forecast by Application (2021-2026)
6 United States Opioid-Induced Constipation Market Facts & Figures
6.1 United States Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
6.2 United States Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
6.3 United States Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
7 Europe Opioid-Induced Constipation Market Facts & Figures
7.1 Europe Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
7.2 Europe Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
7.3 Europe Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
8 China Opioid-Induced Constipation Market Facts & Figures
8.1 China Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
8.2 China Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
8.3 China Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
9 Japan Opioid-Induced Constipation Market Facts & Figures
9.1 Japan Opioid-Induced Constipation Sales Market Share by Company (3015-3030)
9.2 Japan Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
9.3 Japan Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
10 Southeast Asia Opioid-Induced Constipation Market Facts & Figures
10.1 Southeast Asia Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
11 India Opioid-Induced Constipation Market Facts & Figures
11.1 India Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
11.2 India Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
11.3 India Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Opioid-Induced Constipation Business
12.1 Takeda Pharmaceuticals
12.1.1 Takeda Pharmaceuticals Corporation Information
12.1.2 Takeda Pharmaceuticals Business Overview
12.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
12.1.5 Takeda Pharmaceuticals Recent Development
12.2 Bayer
12.2.1 Bayer Corporation Information
12.2.2 Bayer Business Overview
12.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Bayer Opioid-Induced Constipation Products Offered
12.2.5 Bayer Recent Development
12.3 Sanofi
12.3.1 Sanofi Corporation Information
12.3.2 Sanofi Business Overview
12.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Sanofi Opioid-Induced Constipation Products Offered
12.3.5 Sanofi Recent Development
12.4 Mallinckrodt
12.4.1 Mallinckrodt Corporation Information
12.4.2 Mallinckrodt Business Overview
12.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Mallinckrodt Opioid-Induced Constipation Products Offered
12.4.5 Mallinckrodt Recent Development
12.5 Salix (Bausch Health)
12.5.1 Salix (Bausch Health) Corporation Information
12.5.2 Salix (Bausch Health) Business Overview
12.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
12.5.5 Salix (Bausch Health) Recent Development
12.6 AstraZeneca
12.6.1 AstraZeneca Corporation Information
12.6.2 AstraZeneca Business Overview
12.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.6.4 AstraZeneca Opioid-Induced Constipation Products Offered
12.6.5 AstraZeneca Recent Development
12.7 Progenics Pharmaceuticals
12.7.1 Progenics Pharmaceuticals Corporation Information
12.7.2 Progenics Pharmaceuticals Business Overview
12.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
12.7.5 Progenics Pharmaceuticals Recent Development
12.8 Purdue Pharm
12.8.1 Purdue Pharm Corporation Information
12.8.2 Purdue Pharm Business Overview
12.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Purdue Pharm Opioid-Induced Constipation Products Offered
12.8.5 Purdue Pharm Recent Development
12.9 Nektar Therapeutics
12.9.1 Nektar Therapeutics Corporation Information
12.9.2 Nektar Therapeutics Business Overview
12.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Nektar Therapeutics Opioid-Induced Constipation Products Offered
12.9.5 Nektar Therapeutics Recent Development
12.10 Daiichi Sankyo
12.10.1 Daiichi Sankyo Corporation Information
12.10.2 Daiichi Sankyo Business Overview
12.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Daiichi Sankyo Opioid-Induced Constipation Products Offered
12.10.5 Daiichi Sankyo Recent Development
12.11 Prestige
12.11.1 Prestige Corporation Information
12.11.2 Prestige Business Overview
12.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Prestige Opioid-Induced Constipation Products Offered
12.11.5 Prestige Recent Development
12.12 GSK
12.12.1 GSK Corporation Information
12.12.2 GSK Business Overview
12.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.12.4 GSK Opioid-Induced Constipation Products Offered
12.12.5 GSK Recent Development
12.13 Shionogi
12.13.1 Shionogi Corporation Information
12.13.2 Shionogi Business Overview
12.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Shionogi Opioid-Induced Constipation Products Offered
12.13.5 Shionogi Recent Development
13 Opioid-Induced Constipation Manufacturing Cost Analysis
13.1 Opioid-Induced Constipation Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Opioid-Induced Constipation
13.4 Opioid-Induced Constipation Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Opioid-Induced Constipation Distributors List
14.3 Opioid-Induced Constipation Customers
15 Market Dynamics
15.1 Opioid-Induced Constipation Market Trends
15.2 Opioid-Induced Constipation Opportunities and Drivers
15.3 Opioid-Induced Constipation Market Challenges
15.4 Opioid-Induced Constipation Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Opioid-Induced Constipation Sales (K Units) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Opioid-Induced Constipation Sales (K Units) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Opioid-Induced Constipation Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Opioid-Induced Constipation Sales (K Units) by Region (2015-2020)
Table 5. Global Opioid-Induced Constipation Sales Market Share by Region (2015-2020)
Table 6. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Opioid-Induced Constipation Revenue Share by Region (2015-2020)
Table 8. Global Opioid-Induced Constipation Sales (K Units) Forecast by Region (2021-2026)
Table 9. Global Opioid-Induced Constipation Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Opioid-Induced Constipation Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Opioid-Induced Constipation Revenue Share Forecast by Region (2021-2026)
Table 12. Global Opioid-Induced Constipation (K Units) of Key Companies (2015-2020)
Table 13. Global Opioid-Induced Constipation Sales Share by Company (2015-2020)
Table 14. Global Opioid-Induced Constipation Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Opioid-Induced Constipation Revenue Share by Company (2015-2020)
Table 16. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Opioid-Induced Constipation as of 2019)
Table 17. Global Opioid-Induced Constipation Average Price (USD/Unit) of Key Company (2015-2020)
Table 18. Manufacturers Opioid-Induced Constipation Manufacturing Sites and Area Served
Table 19. Manufacturers Opioid-Induced Constipation Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Opioid-Induced Constipation Players
Table 22. Global Opioid-Induced Constipation Sales (K Units) by Type (2015-2020)
Table 23. Global Opioid-Induced Constipation Sales Share by Type (2015-2020)
Table 24. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Opioid-Induced Constipation Price (K Units) by Type (2015-2020)
Table 26. Global Opioid-Induced Constipation Sales Share by Type (2021-2026)
Table 27. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Opioid-Induced Constipation Revenue Share by Type (2021-2026)
Table 29. Global Opioid-Induced Constipation Price (K Units) by Type (2021-2026)
Table 30. Global Opioid-Induced Constipation Sales (K Units) by Application (2015-2020)
Table 31. Global Opioid-Induced Constipation Sales Share by Application (2015-2020)
Table 32. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Opioid-Induced Constipation Price (K Units) by Application (2015-2020)
Table 34. Global Opioid-Induced Constipation Sales (K Units) by Application (2021-2026)
Table 35. Global Opioid-Induced Constipation Sales Share by Application (2021-2026)
Table 36. Global Opioid-Induced Constipation Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Opioid-Induced Constipation Revenue Share by Application (2021-2026)
Table 38. Global Opioid-Induced Constipation Price (K Units) by Application (2021-2026)
Table 39. United States Opioid-Induced Constipation Sales (K Units) by Company (2015-2020)
Table 40. United States Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
Table 41. United States Opioid-Induced Constipation Sales (K Units) by Type (2015-2020)
Table 42. United States Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
Table 43. United States Opioid-Induced Constipation Sales (K Units) by Application (2015-2020)
Table 44. United States Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
Table 45. Europe Opioid-Induced Constipation Sales (K Units) by Company (2015-2020)
Table 46. Europe Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
Table 47. Europe Opioid-Induced Constipation Sales (K Units) by Type (2015-2020)
Table 48. Europe Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
Table 49. Europe Opioid-Induced Constipation Sales (K Units) by Application (2015-2020)
Table 50. Europe Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
Table 51. China Opioid-Induced Constipation Sales (K Units) by Company (2015-2020)
Table 52. China Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
Table 53. China Opioid-Induced Constipation Sales (K Units) by Type (2015-2020)
Table 54. China Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
Table 55. China Opioid-Induced Constipation Sales (K Units) by Application (2015-2020)
Table 56. China Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
Table 57. Japan Opioid-Induced Constipation Sales (K Units) by Company (2015-2020)
Table 58. Japan Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
Table 59. Japan Opioid-Induced Constipation Sales (K Units) by Type (2015-2020)
Table 60. Japan Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
Table 61. Japan Opioid-Induced Constipation Sales (K Units) by Application (2015-2020)
Table 62. Japan Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Opioid-Induced Constipation Sales (K Units) by Company (2015-2020)
Table 64. Southeast Asia Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Opioid-Induced Constipation Sales (K Units) by Type (2015-2020)
Table 66. Southeast Asia Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Opioid-Induced Constipation Sales (K Units) by Type (2015-2020)
Table 68. Southeast Asia Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
Table 69. India Opioid-Induced Constipation Sales (K Units) by Company (2015-2020)
Table 70. India Opioid-Induced Constipation Sales Market Share by Company (2015-2020)
Table 71. India Opioid-Induced Constipation Sales (K Units) by Type (2015-2020)
Table 72. India Opioid-Induced Constipation Sales Market Share by Type (2015-2020)
Table 73. India Opioid-Induced Constipation Sales (K Units) by Application (2015-2020)
Table 74. India Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
Table 75. Takeda Pharmaceuticals Corporation Information
Table 76. Takeda Pharmaceuticals Description and Business Overview
Table 77. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Takeda Pharmaceuticals Opioid-Induced Constipation Product
Table 79. Takeda Pharmaceuticals Recent Development
Table 80. Bayer Corporation Information
Table 81. Bayer Description and Business Overview
Table 82. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Bayer Opioid-Induced Constipation Product
Table 84. Bayer Recent Development
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Sanofi Opioid-Induced Constipation Product
Table 89. Sanofi Recent Development
Table 90. Mallinckrodt Corporation Information
Table 91. Mallinckrodt Description and Business Overview
Table 92. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Mallinckrodt Opioid-Induced Constipation Product
Table 94. Mallinckrodt Recent Development
Table 95. Salix (Bausch Health) Corporation Information
Table 96. Salix (Bausch Health) Description and Business Overview
Table 97. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Salix (Bausch Health) Opioid-Induced Constipation Product
Table 99. Salix (Bausch Health) Recent Development
Table 100. AstraZeneca Corporation Information
Table 101. AstraZeneca Description and Business Overview
Table 102. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. AstraZeneca Opioid-Induced Constipation Product
Table 104. AstraZeneca Recent Development
Table 105. Progenics Pharmaceuticals Corporation Information
Table 106. Progenics Pharmaceuticals Description and Business Overview
Table 107. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Progenics Pharmaceuticals Opioid-Induced Constipation Product
Table 109. Progenics Pharmaceuticals Recent Development
Table 110. Purdue Pharm Corporation Information
Table 111. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 112. Purdue Pharm Description and Business Overview
Table 113. Purdue Pharm Opioid-Induced Constipation Product
Table 114. Purdue Pharm Recent Development
Table 115. Nektar Therapeutics Corporation Information
Table 116. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Nektar Therapeutics Description and Business Overview
Table 118. Nektar Therapeutics Opioid-Induced Constipation Product
Table 119. Nektar Therapeutics Recent Development
Table 120. Daiichi Sankyo Corporation Information
Table 121. Daiichi Sankyo Description and Business Overview
Table 122. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 123. Daiichi Sankyo Opioid-Induced Constipation Product
Table 124. Daiichi Sankyo Recent Development
Table 125. Prestige Corporation Information
Table 126. Prestige Description and Business Overview
Table 127. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 128. Prestige Opioid-Induced Constipation Product
Table 129. Prestige Recent Development
Table 130. GSK Corporation Information
Table 131. GSK Description and Business Overview
Table 132. GSK Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 133. GSK Opioid-Induced Constipation Product
Table 134. GSK Recent Development
Table 135. Shionogi Corporation Information
Table 136. Shionogi Description and Business Overview
Table 137. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 138. Shionogi Opioid-Induced Constipation Product
Table 139. Shionogi Recent Development
Table 140. Production Base and Market Concentration Rate of Raw Material
Table 141. Key Suppliers of Raw Materials
Table 142. Opioid-Induced Constipation Distributors List
Table 143. Opioid-Induced Constipation Customers List
Table 144. Opioid-Induced Constipation Market Key Trends
Table 145. Opioid-Induced Constipation Key Opportunities and Drivers
Table 146. Opioid-Induced Constipation Market Challenges
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid-Induced Constipation Product Picture
Figure 2. Global Opioid-Induced Constipation Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Opioid-Induced Constipation Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Pharmacy Examples
Figure 8. Global Opioid-Induced Constipation Sales (K Units) Growth Rate (2015-2026)
Figure 9. Global Opioid-Induced Constipation Revenue (US$ Million) Growth Rate (2015-2026)
Figure 10. Global Opioid-Induced Constipation Price Trends Growth Rate (2015-2026) (USD/Unit)
Figure 11. Global Opioid-Induced Constipation Revenue Market Share by Region: 2015 VS 2020
Figure 12. Global Opioid-Induced Constipation Revenue Market Share by Region: 2021 VS 2026
Figure 13. United States Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2015-2026)
Figure 14. United States Opioid-Induced Constipation Sales (K Units) Growth Rate (2015-2026)
Figure 15. Europe Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. Europe Opioid-Induced Constipation Sales (Million USD) Growth Rate (2015-2026)
Figure 17. China Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. China Opioid-Induced Constipation Sales (Million USD) and Growth Rate (2015-2026)
Figure 19. Japan Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. Japan Opioid-Induced Constipation Sales (Million USD) Growth Rate (2015-2026)
Figure 21. Southeast Asia Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Opioid-Induced Constipation Sales (Million USD) Growth Rate (2015-2026)
Figure 23. India Opioid-Induced Constipation Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. India Opioid-Induced Constipation Sales (Million USD) Growth Rate (2015-2026)
Figure 25. Global 5 Largest Opioid-Induced Constipation Players Market Share by Revenue in Opioid-Induced Constipation 2015 & 2019
Figure 26. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 27. Global Opioid-Induced Constipation Revenue Share by Type (2015-2020)
Figure 28. Global Opioid-Induced Constipation Revenue Growth Rate by Type in 2015 & 2019
Figure 29. Global Opioid-Induced Constipation Revenue Share by Application (2015-2020)
Figure 30. Global Opioid-Induced Constipation Revenue Growth Rate by Application in 2015 & 2019
Figure 31. United States Opioid-Induced Constipation Sales Market Share by Type in 2019
Figure 32. United States Opioid-Induced Constipation Sales Market Share by Type in 2019
Figure 33. Europe Opioid-Induced Constipation Sales Market Share by Company in 2019
Figure 34. Europe Opioid-Induced Constipation Sales Market Share by Type in 2019
Figure 35. Europe Opioid-Induced Constipation Sales Market Share by Application in 2019
Figure 36. China Opioid-Induced Constipation Sales Market Share by Company in 2019
Figure 37. China Opioid-Induced Constipation Sales Market Share by Type in 2019
Figure 38. China Opioid-Induced Constipation Sales Market Share by Application in 2019
Figure 39. Japan Opioid-Induced Constipation Sales Market Share by Company in 2019
Figure 40. Japan Opioid-Induced Constipation Sales Market Share by Type in 2019
Figure 41. Japan Opioid-Induced Constipation Sales Market Share by Application in 2019
Figure 42. Southeast Asia Opioid-Induced Constipation Sales Market Share by Company in 2019
Figure 43. Southeast Asia Opioid-Induced Constipation Sales Market Share by Type in 2019
Figure 44. Southeast Asia Opioid-Induced Constipation Sales Market Share by Application in 2019
Figure 45. India Opioid-Induced Constipation Sales Market Share by Company in 2019
Figure 46. India Opioid-Induced Constipation Sales Market Share by Type in 2019
Figure 47. India Opioid-Induced Constipation Sales Market Share by Application in 2019
Figure 48. Key Raw Materials Price Trend
Figure 49. Manufacturing Cost Structure of Opioid-Induced Constipation
Figure 50. Manufacturing Process Analysis of Opioid-Induced Constipation
Figure 51. Opioid-Induced Constipation Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Porter's Five Forces Analysis
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
便秘治療薬の世界市場レポート2020 Market Analysis and Insights: Global Constipation Treatment Drug Market The global Constipation Treatment Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Constipation Treatment Drug Scope and Market Size The global…- 便秘薬による過敏性腸症候群の世界市場レポート2020 The symptoms of IBS-C include abdominal pain and discomfort, along with changes in bowel function. Bloating and/or gas also may happen. Changes in bowel function may include straining, infrequent stools, hard or lumpy stools, and/or a feeling that the bowel does not empty completely. Market Analysis…
- 非オピオイド疼痛パッチの世界市場レポート2020 Market Analysis and Insights: Global Non-opioid Pain Patch Market The global Non-opioid Pain Patch market size is projected to reach US$ 759.7 million by 2026, from US$ 650.9 million in 2020, at a CAGR of 2.6% during 2021-2026. Global Non-opioid Pain Patch Scope and Market Size The global Non-opioid…
- CINV（化学療法に伴う悪心・嘔吐）治療薬の世界市場レポート2020 Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs …
- 形状記憶ポリマーの世界市場レポート2020 Market Analysis and Insights: Global Shape Memory Polymer Market The global Shape Memory Polymer market size is projected to reach US$ 491.1 million by 2026, from US$ 301 million in 2020, at a CAGR of 8.5% during 2021-2026. Global Shape Memory Polymer Scope and Market Size The global Shape Memory Po…